Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of MannKind
So what: The news of the day was the FDA delayed its decision on inhaled insulin product Afrezza until around Jan. 26. Analysts are having a tough time figuring out if this is bearish or bullish news, but the bulls took hold early this morning.
Now what: Bulls are interpreting it as a sign the FDA is diligently looking at the application and just needs more time to review the latest information. Bears see this as a sign the FDA doesn't think Afrezza is urgent. Today's news doesn't appear to provide a lot of conviction one way or the other. I don't think today should change your opinion going forward; it just delays the verdict everyone wants to hear.
Interested in more info on MannKind? Add it to your watchlist.